Stomach Cancer Drugs Market - Latest Advancement And Industry Analysis (2024- 2032)

Stomach Cancer Drugs Market Synopsis:

Stomach Cancer Drugs Market Size Was Valued at USD 4.8 Billion in 2023, and is Projected to Reach USD 14.4 Billion by 2032, Growing at a CAGR of 12.9% From 2024-2032.

The stomach cancer drugs market includes the strategic products for the management of gastric cancer, which is a form of cancer that begins in the stomach walls. This market covers the therapies such as targeted therapy, immunotherapy, chemotherapy, and combination therapies that are used for the treatment or prevention of the disease by restraining the growth of tumour or by balancing the immune system. Gastric cancer is the fourth most common cancer and a major cause of cancer death in the global population especially among the East Asian population. This field has developed much due to factors such as increasing rate of cancer, demand for better technologies and materials in treating this disease, and governments focusing much on early detection and treatment. The market also has a number of advantages and it is based on the continuous clinical trials as well as new drug approvals and pipeline of novel therapies.

The market for stomach cancer drugs has experienced a steady growth over the years due to the ever rising incidence of stomach cancer especially in regions with high burden of H. Pylori infection and poor diet. Advances in diagnostic techniques combined with increased understanding of early signs and symptoms have enhanced early identification leading to need for efficient and adequate therapies. A big emphasis has been placed on small molecule targeted paid therapies and immunotherapies which are more effective and less toxic than conventional chemotherapies. Such a transition to individualized approach has changed the orientation of stomach cancer treatment special focus being on biomarkers and genomic profiles.

Also, healthcare sectors of developed and developing countries have made enhanced availability of cancer therapies through funding strategies and reimbursement policies and therefore have fuelled the market growth. The availability of new classes of biologics and checkpoint inhibitors in the gastric cancer treatment flow gives healthcare providers and patients positive results in cases of the advanced or metastatic cancer. Nevertheless, these therapies are expensive and often unavailable in some areas, which creates important problems for the future, hence the necessity for creating new and reasonable cost models and development of Markets in various countries.

Stomach Cancer Drugs Market Trend Analysis:

Rise of Immunotherapy in Stomach Cancer Treatment

• Immunotherapy, particularly PD-1/PD-L1 inhibitors, a method of attacking cancer cells by building up the body’s immune response, is a key trend that is rapidly gaining popularity in the stomach cancer drugs industry. Immunotherapy is proven to be rather effective in the cases of the stages 3 and 4 gastric cancer when the other types of treatment do not give any results. The pharmaceutical industry companies are currently directing a lot of research on possible immunotherapeutic combinations for improving patient’s outcomes. Moreover, several clinical trials are still ongoing to extend the use of immunotherapies in stage I gastric cancer, which demonstrates that everyone is aware of their possibilities.

Advancements in Targeted Therapies

• The emerging area of targeted therapies, especially when such treatments are more developed to offer a big growth scope to the stomach cancer drugs market. These therapies work by preventing the expression or function of particular molecules or pathway known to contributes to tumorgenesis thus making cancer therapy more targeted. Hunting down HER2 with drugs like trastuzumab has already been proven to work, which can only mean more success in hunting down other biomarkers such as VEGF and MET. Thanks to the rising utilization of new diagnostic methods, including liquid biopsies and next-generation sequencing, the detection of potential therapeutic targets is becoming increasingly selective and granular, thus stimulating the creation of targeted and efficient therapies.

Stomach Cancer Drugs Market Segment Analysis:

Stomach Cancer Drugs Market Segmented on The Basis of Drug Class, Route of Administration, Distribution Channel, and Region.

By Drug Class, PD-1/PD-L1 inhibitors segment is expected to dominate the market during the forecast period

• The PD-1/PD-L1 inhibitors segment is expected to account for the largest share of the stomach cancer drugs market during the forecast period because of the effectiveness of these drugs in treating the advanced and metastatic gastric cancer. These immunotherapies operate depending on the inhibition of the PD-1/PD-L1 pathway, as through which the cancers cells trigger their hiding from investigations by the immune system. Pembrolizumab and nivolumab demonstrate great effectiveness and have become the gold standard for similar drugs concerning patients with MSI-H and/or PD-L1-positive tumor.
• In addition, clinical research and regulatory clearances are now defining a growing application of PD-1/PD-L1 inhibitors in stages earlier than the third in stomach cancer, which is widening their market share. Licensing of multiproduct combination additions of immunotherapy with chemotherapy or targeted therapies is seen among pharma players partnered with research institutions. Such innovations have ensured that PD-1/PD-L1 inhibitors are the mainstay of current stomach cancer management.

By Route of Administration, Oral segment expected to held the largest share

• And, the oral segment is expected to dominate the overall stomach cancer drugs market since it is easier to administer and patients are more likely to adhere to the administration. Oral preparations are far flexible than IV therapies, and the patient can easily take it from the comfort of their homes without constant trips to the hospital. Cancer patients requiring lifelong therapy are usually preferred to have oral drugs because productivity is not much affected by the therapy hence the popularity of oral drugs with the patients and the physicians.
• Also, the increase in the number of oral targeted therapies including tyrosine kinase inhibitors (TKIs) has helped to reinforce this segment’s position. Pharmaceutical manufacturers are also designing specific drug delivery systems and formulations to enhance the improvement of oral drug bioavailability and efficacy, in order to unlock the growth of this segment. This trend is in line with the general global trend aimed at early and convenient detection of cancer that allows improving the quality of life of patients.

Stomach Cancer Drugs Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• In 2023, the market share of Asia-Pacific in the stomach cancer drugs market exceeded 40%. This can be explained by the relatively high incidence of stomach cancer in such countries as China, Japan, and South Korea, where the role of nutritional and Helicobacter pylori factors is maximized. Presence of dominant pharma companies and governmental steps in order to bolster the establishments related to cancer care also boosted the geographies involved in the market. Furthermore, Asia-Pacific region is witnessing a steady increase in clinical trial and tie-ups for research and more, increasing the pace of providing better and new therapies.

Active Key Players in the Stomach Cancer Drugs Market:

• AbbVie Inc. (United States)
• Amgen Inc. (United States)
• Astellas Pharma Inc. (Japan)
• AstraZeneca plc (United Kingdom)
• Bayer AG (Germany)
• Bristol-Myers Squibb Company (United States)
• Daiichi Sankyo Co., Ltd. (Japan)
• Eli Lilly and Company (United States)
• F. Hoffmann-La Roche AG (Switzerland)
• GlaxoSmithKline plc (United Kingdom)
• Johnson & Johnson (United States)
• Merck & Co., Inc. (United States)
• Novartis AG (Switzerland)
• Pfizer Inc. (United States)
• Takeda Pharmaceutical Company Limited (Japan), and Other Active Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Stomach Cancer Drugs Market by Drug Class
 4.1 Stomach Cancer Drugs Market Snapshot and Growth Engine
 4.2 Stomach Cancer Drugs Market Overview
 4.3 PD-1/PD-L1 inhibitors
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 PD-1/PD-L1 inhibitors: Geographic Segmentation Analysis
 4.4 HER2 antagonists
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 HER2 antagonists: Geographic Segmentation Analysis
 4.5 VEGFR2 antagonists
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 VEGFR2 antagonists: Geographic Segmentation Analysis
 4.6 Others
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Others: Geographic Segmentation Analysis

Chapter 5: Stomach Cancer Drugs Market by Route of Administration
 5.1 Stomach Cancer Drugs Market Snapshot and Growth Engine
 5.2 Stomach Cancer Drugs Market Overview
 5.3 Oral
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Oral: Geographic Segmentation Analysis
 5.4 Injectable
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Injectable: Geographic Segmentation Analysis

Chapter 6: Stomach Cancer Drugs Market by Distribution Channel
 6.1 Stomach Cancer Drugs Market Snapshot and Growth Engine
 6.2 Stomach Cancer Drugs Market Overview
 6.3 Hospital Pharmacies
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
 6.4 Specialty & Retail Pharmacies
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Specialty & Retail Pharmacies: Geographic Segmentation Analysis
 6.5 Others
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Others: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Stomach Cancer Drugs Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 ABBVIE INC.
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 AMGEN INC.
 7.4 ASTELLAS PHARMA INC.
 7.5 ASTRAZENECA PLC
 7.6 BAYER AG
 7.7 BRISTOL-MYERS SQUIBB COMPANY
 7.8 DAIICHI SANKYO CO. LTD.
 7.9 ELI LILLY AND COMPANY
 7.10 F. HOFFMANN-LA ROCHE AG
 7.11 GLAXOSMITHKLINE PLC
 7.12 JOHNSON & JOHNSON
 7.13 MERCK & CO. INC.
 7.14 NOVARTIS AG
 7.15 PFIZER INC.
 7.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Stomach Cancer Drugs Market By Region
 8.1 Overview
 8.2. North America Stomach Cancer Drugs Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Drug Class
  8.2.4.1 PD-1/PD-L1 inhibitors
  8.2.4.2 HER2 antagonists
  8.2.4.3 VEGFR2 antagonists
  8.2.4.4 Others
  8.2.5 Historic and Forecasted Market Size By Route of Administration
  8.2.5.1 Oral
  8.2.5.2 Injectable
  8.2.6 Historic and Forecasted Market Size By Distribution Channel
  8.2.6.1 Hospital Pharmacies
  8.2.6.2 Specialty & Retail Pharmacies
  8.2.6.3 Others
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Stomach Cancer Drugs Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Drug Class
  8.3.4.1 PD-1/PD-L1 inhibitors
  8.3.4.2 HER2 antagonists
  8.3.4.3 VEGFR2 antagonists
  8.3.4.4 Others
  8.3.5 Historic and Forecasted Market Size By Route of Administration
  8.3.5.1 Oral
  8.3.5.2 Injectable
  8.3.6 Historic and Forecasted Market Size By Distribution Channel
  8.3.6.1 Hospital Pharmacies
  8.3.6.2 Specialty & Retail Pharmacies
  8.3.6.3 Others
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
 8.4. Western Europe Stomach Cancer Drugs Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Drug Class
  8.4.4.1 PD-1/PD-L1 inhibitors
  8.4.4.2 HER2 antagonists
  8.4.4.3 VEGFR2 antagonists
  8.4.4.4 Others
  8.4.5 Historic and Forecasted Market Size By Route of Administration
  8.4.5.1 Oral
  8.4.5.2 Injectable
  8.4.6 Historic and Forecasted Market Size By Distribution Channel
  8.4.6.1 Hospital Pharmacies
  8.4.6.2 Specialty & Retail Pharmacies
  8.4.6.3 Others
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
 8.5. Asia Pacific Stomach Cancer Drugs Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Drug Class
  8.5.4.1 PD-1/PD-L1 inhibitors
  8.5.4.2 HER2 antagonists
  8.5.4.3 VEGFR2 antagonists
  8.5.4.4 Others
  8.5.5 Historic and Forecasted Market Size By Route of Administration
  8.5.5.1 Oral
  8.5.5.2 Injectable
  8.5.6 Historic and Forecasted Market Size By Distribution Channel
  8.5.6.1 Hospital Pharmacies
  8.5.6.2 Specialty & Retail Pharmacies
  8.5.6.3 Others
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Stomach Cancer Drugs Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Drug Class
  8.6.4.1 PD-1/PD-L1 inhibitors
  8.6.4.2 HER2 antagonists
  8.6.4.3 VEGFR2 antagonists
  8.6.4.4 Others
  8.6.5 Historic and Forecasted Market Size By Route of Administration
  8.6.5.1 Oral
  8.6.5.2 Injectable
  8.6.6 Historic and Forecasted Market Size By Distribution Channel
  8.6.6.1 Hospital Pharmacies
  8.6.6.2 Specialty & Retail Pharmacies
  8.6.6.3 Others
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Stomach Cancer Drugs Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Drug Class
  8.7.4.1 PD-1/PD-L1 inhibitors
  8.7.4.2 HER2 antagonists
  8.7.4.3 VEGFR2 antagonists
  8.7.4.4 Others
  8.7.5 Historic and Forecasted Market Size By Route of Administration
  8.7.5.1 Oral
  8.7.5.2 Injectable
  8.7.6 Historic and Forecasted Market Size By Distribution Channel
  8.7.6.1 Hospital Pharmacies
  8.7.6.2 Specialty & Retail Pharmacies
  8.7.6.3 Others
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research